ClinicalTrials.gg
Not yet recruitingNCT06665763Updated Nov 1, 2024

The Lactate Project: Investigating the Impact of Lactate to Preserve Vital Organ Blood Supply and Function in Heart and Brain

An interventional study of Sodium Lactate Solution and Saline infusion (placebo) in Healthy and Lactate Blood Increase, sponsored by University of Aarhus. Not yet recruiting at 2 sites in Denmark. Open to participants aged 55 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by University of Aarhus · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
55 Years to 75 Years
Sex
All
01

Study summary

The aim of the proposed study is to investigate the effect of increased plasma lactate concentrations on the heart and brain's metabolism of other energy sources, primarily glucose in the brain and glucose and FFA in the heart.

The investigator hypothesize that:

  • An acute increase in lactate plasma concentration will decrease cerebral glucose uptake and increase cerebral blood flow
  • An acute increase in lactate plasma concentration will decrease palmitate and glucose uptake in the myocardium, and increase myocardial perfusion
Read the detailed description

SCREENING VISIT

During the initial screening visit, the investigators will inform all potential volunteers about the project, and volunteers will have the chance to ask questions about participation in the project.

The investigators will register the following data

  1. Medical history to assess exclusion criteria
  2. Weight, height, BMI
  3. Standard medical examination including pulse, blood pressure and an ECG

After assessment of inclusion- and exclusion criteria remaining volunteers will be offered to participate in the project. The investigators will screen potential volunteers with the following blood samples: haemoglobin, HbA1c, glucose, cholesterol, triglyceride, TSH, creatinine, albumin, sodium, potassium, ALAT, ASAT, bilirubin and coagulation parameters.

Blood samples and randomization will not take place until volunteers have signed the informed consent form.

MAGNETIC RESONANCE IMAGING (MRI) SCAN

The investigators will perform a cerebral MRI for the purpose of anatomical localisation for alignment with the PET scans on the 1st and 2nd study day.

1st STUDY DAY:

The volunteers will arrive fasted (8 hours) at the Department of Nuclear Medicine \& PET-Centre at 7.30 a.m., where the subject will have an arterial catheter placed for arterial blood sampling during PET scans as well as two venous catheters for blood sampling and continued administration of intravenous fluids (saline or Na-lactate) and adenosine. At 9.00 a.m., we will start the Na-lactate or saline infusion.

From 9.30 a.m., the investigators will perform PET scans with administration of relevant PET tracers preceding each scan. The investigators will perform PET scans in the following order:

  1. Dynamic PET scan with [15O]H2O in order to assess cerebral perfusion.
  2. Dynamic PET scan with [15O]H2O in order to assess myocardial perfusion.
  3. Stress test using an adenosine infusion during a dynamic PET scan with [15O]H2O to assess coronary flow reserve (CFR) in the heart.
  4. Dynamic PET scan with [11C]Palmitate to assess uptake, oxidation and re-esterification of FFA in the heart.
  5. Dynamic PET scan with [11C]Acetate to asses oxygen and energy expenditure in the heart.
  6. Dynamic whole-body PET scan with [18F]FDG to assess glucose uptake in the heart and brain.

Following the [11C]Acetate scan the investigators will administrate a continued infusion of insulin (0,3 mIE/kg/min) and 20% glucose throughout the rest of the study day in order to achieve hyperinsulinemic-euglycemic conditions (clamp conditions). To correct for attenuation, we will perform three lowdose, non-contrast enhanced CT scans over the course of the study day. The investigators will draw blood samples every hour.

2nd STUDY DAY

The PET scan regime during the 2nd study day is identical to the 1st study day. If volunteers were administered Na-lactate during the 1st study day they will be administered saline during the 2nd studyday and vice versa.

02

Conditions studied

  • Healthy
  • Lactate Blood Increase

Browse trials for

Keywords

  • Human metabolism
  • Substrate utilization
  • Cerebral blod flow
  • Cardiac metabolism
  • Cerebral metabolism
  • Cardiac perfusion
  • Glucose metabolism
  • Lipid metabolism
  • Lactate utilization
03

In context

Hyperlactatemia

50 studies on the registry are indexed under Hyperlactatemia; 7 are open to participants now.

This study's planned enrollment of 8 is below the median of 38 across 32 interventional studies indexed under Hyperlactatemia.

Browse Hyperlactatemia studies →

Lead sponsor

University of Aarhus is the lead sponsor of 1,300 studies on the registry; 189 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 55-75 years
  2. Male or female
  3. 20-35 kg/m2
  4. Signed form

Exclusion criteria

Exclusion Criteria:

  1. heart, lung, kidney, kidney, liver, endocrine or malignant disease basedon information obtained during an initial screening visit as well as blood samples and an .
  2. Blood donation within the last 3 months
  3. Smoking
  4. Alcohol- or substance abuse
  5. Participation in other clinical trials involving ionized radiation within the last 6 months
  6. Claustrophobia
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Na-Lactate infusion

    Other: Sodium Lactate Solution

  • Placebo comparator
    Saline infusion (Placebo)

    Other: Saline infusion (placebo)

Interventions

  • OtherSodium Lactate Solution

    Infusion of sodium-lactate solution

  • OtherSaline infusion (placebo)

    NaCl solution

    Also known as: NaCl

06

What researchers measure

Primary outcomes

  1. Cerebral glucose uptake

    Cerebral glucose uptake (\[18F\]FDG PET scan) under basal and hyperinsulinemic- euglycemic conditions (clamp conditions).

    Time frame: From T=300-360 (minutes)

Secondary outcomes

  1. Cerebral blood flow

    Cerebral blood flow (\[15O\]H2O PET scan)

    Time frame: T = 0-10 (minutes)

  2. Myocardial perfusion

    Myocardial perfusion (\[15O\]H2O PET scan)

    Time frame: T = 0-10 (minutes)

  3. Myocardial glucose uptake

    Myocardial glucose uptake (\[18F\]FDG PET scan)

    Time frame: T = 300-360 (minutes)

  4. Myocardial FFA uptake and oxidation

    Myocardial FFA uptake and oxidation (\[11C\]Palmitate PET scan)

    Time frame: T = 30-70 (minutes)

  5. Myocardial contractility

    Myocardial contractility (ejection fraction based on ECG-gated PET scan)

    Time frame: T=0-10 (minutes)

  6. Myocardial oxygen consumption and efficiency

    Myocardial oxygen consumption and efficiency (\[11C\]Acetate PET scan)

    Time frame: T=150-180 (minutes)

  7. Blood sampling

    A number of cardiometabolic blood samples will be collected during the whole study day.

    Time frame: T = -60 to 360 (minutes)

07

Study locations

2 sites
  • Medical Research Laboratories/Steno Diabetes Center Aarhus
    Aarhus, N 8000, Denmark
  • Department of Nuclear Medicine & PET-Centre
    Aarhus, N 8200, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06665763
Responsible party
Sponsor
First posted
Oct 30, 2024
Start date
Feb 1, 2025 (estimated)
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Nov 1, 2024

Study contacts

Esben Søndergaard, MD, PhD
Contact
Esben.sondergaard@clin.au.dk
004528730943
Jens Voigt, MD
Contact
Jens.voigt@clin.au.dk
0026395294

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion